Cargando…

Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. A comprehensive and detailed understanding of COPD care pathways from pre-diagnosis to acute care is required to understand the common barriers to optimal COPD care across diverse health s...

Descripción completa

Detalles Bibliográficos
Autores principales: Meiwald, Anne, Gara-Adams, Rupert, Rowlandson, Aleix, Ma, Yixuan, Watz, Henrik, Ichinose, Masakazu, Scullion, Jane, Wilkinson, Tom, Bhutani, Mohit, Weston, Georgie, Adams, Elisabeth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255283/
https://www.ncbi.nlm.nih.gov/pubmed/35801119
http://dx.doi.org/10.2147/COPD.S360983
_version_ 1784740891882160128
author Meiwald, Anne
Gara-Adams, Rupert
Rowlandson, Aleix
Ma, Yixuan
Watz, Henrik
Ichinose, Masakazu
Scullion, Jane
Wilkinson, Tom
Bhutani, Mohit
Weston, Georgie
Adams, Elisabeth J
author_facet Meiwald, Anne
Gara-Adams, Rupert
Rowlandson, Aleix
Ma, Yixuan
Watz, Henrik
Ichinose, Masakazu
Scullion, Jane
Wilkinson, Tom
Bhutani, Mohit
Weston, Georgie
Adams, Elisabeth J
author_sort Meiwald, Anne
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. A comprehensive and detailed understanding of COPD care pathways from pre-diagnosis to acute care is required to understand the common barriers to optimal COPD care across diverse health systems. METHODS: Country-specific COPD care pathways were created for four high-income countries using international recommendations and country-specific guidelines, then populated with published epidemiological, clinical, and economic data. To refine and validate the pathways, semi-structured interviews using pre-prepared discussion guides and country-specific pathway maps were held with twenty-four primary and secondary care respiratory healthcare professionals. Thematic analysis was then performed on the interview transcripts. RESULTS: The COPD care pathway showed broad consistency across the countries. Three key themes relating to barriers in optimal COPD management were identified across the countries: journey to diagnosis, treatment, and the impact of COVID-19. Common barriers included presentation to healthcare with advanced COPD, low COPD consideration, and sub-optimal acute and chronic disease management. COVID-19 has negatively impacted disease management across the pathway but presents opportunities to retain virtual consultations. Structural factors such as insurance and short duration of appointments also impacted the diagnosis and management of COPD. CONCLUSION: COPD is an important public health issue that needs urgent prioritization. The use of Evidenced Care Pathways with decision-makers can facilitate evidence-based decision making on interventions and policies to improve care and outcomes for patients and reduce unnecessary resource use and associated costs for the healthcare provider/payer.
format Online
Article
Text
id pubmed-9255283
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92552832022-07-06 Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care Meiwald, Anne Gara-Adams, Rupert Rowlandson, Aleix Ma, Yixuan Watz, Henrik Ichinose, Masakazu Scullion, Jane Wilkinson, Tom Bhutani, Mohit Weston, Georgie Adams, Elisabeth J Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. A comprehensive and detailed understanding of COPD care pathways from pre-diagnosis to acute care is required to understand the common barriers to optimal COPD care across diverse health systems. METHODS: Country-specific COPD care pathways were created for four high-income countries using international recommendations and country-specific guidelines, then populated with published epidemiological, clinical, and economic data. To refine and validate the pathways, semi-structured interviews using pre-prepared discussion guides and country-specific pathway maps were held with twenty-four primary and secondary care respiratory healthcare professionals. Thematic analysis was then performed on the interview transcripts. RESULTS: The COPD care pathway showed broad consistency across the countries. Three key themes relating to barriers in optimal COPD management were identified across the countries: journey to diagnosis, treatment, and the impact of COVID-19. Common barriers included presentation to healthcare with advanced COPD, low COPD consideration, and sub-optimal acute and chronic disease management. COVID-19 has negatively impacted disease management across the pathway but presents opportunities to retain virtual consultations. Structural factors such as insurance and short duration of appointments also impacted the diagnosis and management of COPD. CONCLUSION: COPD is an important public health issue that needs urgent prioritization. The use of Evidenced Care Pathways with decision-makers can facilitate evidence-based decision making on interventions and policies to improve care and outcomes for patients and reduce unnecessary resource use and associated costs for the healthcare provider/payer. Dove 2022-07-01 /pmc/articles/PMC9255283/ /pubmed/35801119 http://dx.doi.org/10.2147/COPD.S360983 Text en © 2022 Meiwald et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Meiwald, Anne
Gara-Adams, Rupert
Rowlandson, Aleix
Ma, Yixuan
Watz, Henrik
Ichinose, Masakazu
Scullion, Jane
Wilkinson, Tom
Bhutani, Mohit
Weston, Georgie
Adams, Elisabeth J
Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title_full Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title_fullStr Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title_full_unstemmed Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title_short Qualitative Validation of COPD Evidenced Care Pathways in Japan, Canada, England, and Germany: Common Barriers to Optimal COPD Care
title_sort qualitative validation of copd evidenced care pathways in japan, canada, england, and germany: common barriers to optimal copd care
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255283/
https://www.ncbi.nlm.nih.gov/pubmed/35801119
http://dx.doi.org/10.2147/COPD.S360983
work_keys_str_mv AT meiwaldanne qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT garaadamsrupert qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT rowlandsonaleix qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT mayixuan qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT watzhenrik qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT ichinosemasakazu qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT scullionjane qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT wilkinsontom qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT bhutanimohit qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT westongeorgie qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare
AT adamselisabethj qualitativevalidationofcopdevidencedcarepathwaysinjapancanadaenglandandgermanycommonbarrierstooptimalcopdcare